Literature DB >> 2860834

Takayasu's arteritis and its therapy.

J H Shelhamer, D J Volkman, J E Parrillo, T J Lawley, M R Johnston, A S Fauci.   

Abstract

Twenty patients with Takayasu's arteritis were followed prospectively for an average of 4.6 years. Sixteen patients with active inflammatory Takayasu's arteritis were treated with glucocorticosteroids; eight responded to therapy. Six patients had clinical or angiographic progression of their vasculitis on daily corticosteroid therapy. These patients were then given cyclophosphamide together with prednisone on alternate days. Four of these 6 patients had no progression of vascular lesions while receiving cyclophosphamide; two had progression of vascular lesions after 30 and 48 months of therapy. Vascular reconstructive surgery was successful in 7 patients who tolerated a total of 13 vascular surgical procedures without major complications. One bypass graft occluded after 13 months and was revised. With corticosteroid therapy, cytotoxic therapy, and surgery, no deaths due to Takayasu's arteritis or its treatment have occurred.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860834     DOI: 10.7326/0003-4819-103-1-121

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  48 in total

Review 1.  The use of immunosuppressive and cytotoxic drugs in non-malignant disease.

Authors:  P A Brogan; M J Dillon
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

Review 2.  Hereditary factors of Takayasu arteritis.

Authors:  F Numano
Journal:  Heart Vessels Suppl       Date:  1992

3.  Intracranial haemodynamics in Takayasu's arteritis.

Authors:  D G Grosset; J Patterson; I Bone
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

Review 4.  Takayasu arteritis: a review.

Authors:  S L Johnston; R J Lock; M M Gompels
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

5.  Endovascular stent implantation for isolated pulmonary arterial stenosis caused by Takayasu's arteritis.

Authors:  De Li; Shuangtao Ma; Gang Li; Jinsong Chen; Bing Tang; Xin Zhang; Dachun Yang; Yongjian Yang
Journal:  Clin Res Cardiol       Date:  2010-04-20       Impact factor: 5.460

Review 6.  Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature.

Authors:  P I Novikov; I O Smitienko; S V Moiseev
Journal:  Clin Rheumatol       Date:  2013-09-01       Impact factor: 2.980

Review 7.  New indications for biological therapies.

Authors:  Mariagrazia Catanoso; Nicolò Pipitone; Luca Magnani; Luigi Boiardi; Carlo Salvarani
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 8.  Takayasu's arteritis: a review of the literature.

Authors:  Silvia Maffei; Michela Di Renzo; Giovanni Bova; Alberto Auteri; Anna Laura Pasqui
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

9.  [Recommendations of the European League Against Rheumatism (EULAR) for the treatment of "large-vessel vasculitides"].

Authors:  E Wipfler-Freissmuth; F Moosig; M Schirmer
Journal:  Z Rheumatol       Date:  2009-05       Impact factor: 1.372

10.  A case of MCTD overlapped by Takayasu's arteritis, presenting Raynaud's phenomenon as the initial manifestation of both diseases.

Authors:  Mie Jin Lim; Seong Ryul Kwon; Sang Gu Kim; Won Park
Journal:  Rheumatol Int       Date:  2008-10-11       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.